LENZ Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
LENZ Therapeutics Inc is not a strong buy for a beginner, long-term investor at this time. The lack of positive trading signals, neutral technical indicators, declining analyst price targets, and weak financial performance suggest that waiting for further developments or a clearer upward trend would be prudent.
The MACD is positive but contracting, RSI is neutral at 34.02, and moving averages are converging, indicating no clear trend. The stock is trading near its support level of 9.163, with resistance at 10.233.
There are no significant positive catalysts at this time. The options market shows slight bullish sentiment, but it is not strong enough to act as a major driver.
Analyst price targets have been consistently lowered, reflecting reduced confidence in the company's growth potential. The stock trend analysis indicates a high probability of further short-term declines.
In Q4 2025, revenue remained flat YoY at $1,588,000. Net income improved but remains negative at -$35,896,000. EPS improved to -1.15, but the company is still unprofitable. Gross margin is strong at 73.68%, but growth is stagnant.
Analysts maintain a Buy rating but have significantly lowered price targets over the past few months, citing slower-than-expected product launch and revenue growth. The most recent price target is $26, down from $56 earlier this year.
